495 related articles for article (PubMed ID: 24769013)
21. A reduced dose of fluconazole as primary antifungal prophylaxis is not associated with increased risk of invasive fungal infections after allogeneic stem cell transplantation from a HLA identical sibling.
Sarina B; Mariotti J; Bramanti S; Morabito L; Crocchiolo R; Rimondo A; Tordato F; Pocaterra D; Casari E; De Philippis C; Carlo-Stella C; Santoro A; Castagna L
Transpl Infect Dis; 2018 Aug; 20(4):e12906. PubMed ID: 29668124
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing haplo-identical hematopoietic SCT.
El-Cheikh J; Venton G; Crocchiolo R; Fürst S; Faucher C; Granata A; Oudin C; Coso D; Bouabdallah R; Vey N; Duran S; Fougereau E; Berger P; Chabannon C; Blaise D
Bone Marrow Transplant; 2013 Nov; 48(11):1472-7. PubMed ID: 23749104
[TBL] [Abstract][Full Text] [Related]
23. Incidence and outcome of invasive fungal diseases after allogeneic hematopoietic stem cell transplantation: A Swiss transplant cohort study.
Kuster S; Stampf S; Gerber B; Baettig V; Weisser M; Gerull S; Medinger M; Passweg J; Schanz U; Garzoni C; Berger C; Chalandon Y; Mueller NJ; van Delden C; Neofytos D; Khanna N;
Transpl Infect Dis; 2018 Dec; 20(6):e12981. PubMed ID: 30144374
[TBL] [Abstract][Full Text] [Related]
24. Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease.
Luu Tran H; Mahmoudjafari Z; Rockey M; Henry D; Grauer D; Aljitawi O; Abhyankar S; Ganguly S; Lin T; McGuirk J
J Oncol Pharm Pract; 2016 Apr; 22(2):228-34. PubMed ID: 25471252
[TBL] [Abstract][Full Text] [Related]
25. Feasibility and effectiveness of posaconazole prophylaxis in combination with micafungin bridging for patients undergoing allogeneic stem cell transplantation: a 6-yr analysis from the cologne cohort for neutropenic patients.
Vehreschild MJ; von Bergwelt-Baildon M; Tran L; Shimabukuro-Vornhagen A; Wisplinghoff H; Bangard C; Cornely OA; Vehreschild JJ
Eur J Haematol; 2014 Nov; 93(5):400-6. PubMed ID: 24798021
[TBL] [Abstract][Full Text] [Related]
26. Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients.
Park S; Kim K; Jang JH; Kim SJ; Kim WS; Chung DR; Kang CI; Peck KR; Jung CW
J Infect; 2016 Nov; 73(5):496-505. PubMed ID: 27394404
[TBL] [Abstract][Full Text] [Related]
27. [Clinical investigation of reduced-dose voriconazole on primary prevention in invasive fungal disease after allogeneic hematopoietic stem cell transplantation].
Qiu Z; Ren H; Cen X; Ou J; Xu W; Wang M; Wang L; Dong Y; Li Y; Liu W; Sun Y; Liang Z; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2014 Jul; 35(7):577-80. PubMed ID: 25052595
[TBL] [Abstract][Full Text] [Related]
28. Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study.
Harrison N; Mitterbauer M; Tobudic S; Kalhs P; Rabitsch W; Greinix H; Burgmann H; Willinger B; Presterl E; Forstner C
BMC Infect Dis; 2015 Dec; 15():584. PubMed ID: 26715563
[TBL] [Abstract][Full Text] [Related]
29. Combination antifungal treatment for invasive fungal disease after hematopoietic stem cell transplantation in children with hematological disorders.
Qiu KY; Liao XY; Fang JP; Xu HG; Li Y; Huang K; Zhou DH
Transpl Infect Dis; 2019 Jun; 21(3):e13066. PubMed ID: 30859662
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of "RISK" Study.
Choi JK; Cho SY; Yoon SS; Moon JH; Kim SH; Lee JH; Kim JS; Cheong JW; Jang JH; Seo BJ; Kim YJ; Lee HJ; Lee J; Lee JW; Lee DG
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1773-1779. PubMed ID: 28668492
[TBL] [Abstract][Full Text] [Related]
31. Allogeneic hematopoietic stem cell transplantation after surgical resection of pulmonary aspergillosis in 5 patients with acute leukemia.
Motohashi K; Ito S; Hagihara M; Sakai R; Tanaka M; Kawano T; Maruta A; Ishigatsubo Y; Kanamori H
Rinsho Ketsueki; 2009 May; 50(5):430-4. PubMed ID: 19483405
[TBL] [Abstract][Full Text] [Related]
32. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
[TBL] [Abstract][Full Text] [Related]
33. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
34. Incidence of invasive aspergillosis among allogeneic hematopoietic stem cell transplant patients receiving voriconazole prophylaxis.
Siwek GT; Pfaller MA; Polgreen PM; Cobb S; Hoth P; Magalheas-Silverman M; Diekema DJ
Diagn Microbiol Infect Dis; 2006 Jul; 55(3):209-12. PubMed ID: 16626917
[TBL] [Abstract][Full Text] [Related]
35. Positive results of serum galactomannan assays and pulmonary computed tomography predict the higher response rate of empirical antifungal therapy in patients undergoing allogeneic hematopoietic stem cell transplantation.
Ji Y; Xu LP; Liu DH; Chen YH; Han W; Zhang XH; Chen H; Wang Y; Wang JZ; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2011 May; 17(5):759-64. PubMed ID: 21056109
[TBL] [Abstract][Full Text] [Related]
36. [Efficacy and safety of intravenous itraconazole in different antifungal strategies for patients undergoing intensive chemotherapy or hematopoietic stem cell transplantation].
Ji Y; Xu L; Huang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):689-93. PubMed ID: 25152113
[TBL] [Abstract][Full Text] [Related]
37. Aspergillus infections in allogeneic stem cell transplant recipients: have we made any progress?
Jantunen E; Anttila VJ; Ruutu T
Bone Marrow Transplant; 2002 Dec; 30(12):925-9. PubMed ID: 12476286
[TBL] [Abstract][Full Text] [Related]
38. Comparison of posaconazole versus weekly amphotericin B lipid complex for the prevention of invasive fungal infections in hematopoietic stem-cell transplantation.
Chaftari AM; Hachem RY; Ramos E; Kassis C; Campo M; Jiang Y; Prince RA; Wang W; Raad II
Transplantation; 2012 Aug; 94(3):302-8. PubMed ID: 22814329
[TBL] [Abstract][Full Text] [Related]
39. Risk factors for invasive aspergillosis and related mortality in recipients of allogeneic SCT from alternative donors: an analysis of 306 patients.
Mikulska M; Raiola AM; Bruno B; Furfaro E; Van Lint MT; Bregante S; Ibatici A; Del Bono V; Bacigalupo A; Viscoli C
Bone Marrow Transplant; 2009 Sep; 44(6):361-70. PubMed ID: 19308042
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Girmenia C; Barosi G; Aversa F; Bacigalupo A; Barbui T; Baronciani D; Bosi A; Candoni A; Locasciulli A; Locatelli F; Menichetti F; Musso M; Viscoli C; Rambaldi A
Clin Infect Dis; 2009 Oct; 49(8):1226-36. PubMed ID: 19772390
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
